Penticton is one of four B.C. communities now enrolling volunteers in an international study of an investigational psilocybin treatment for adults living with post-traumatic stress disorder
PENTICTON, B.C. — November 19th 2026 — Medical Arts Health Research Group has begun enrolling volunteers in Penticton for an international clinical trial evaluating a potential new treatment for adults living with post-traumatic stress disorder (PTSD). Penticton joins Kelowna, Kamloops and North Vancouver as one of four B.C. communities now enrolling.
The study, known as COMP 202, is evaluating an investigational form of psilocybin. The trial is being conducted under Health Canada and research ethics oversight. Participation is voluntary, and every interested person is carefully screened by a study doctor to determine whether the study is a safe and appropriate fit.
This summer, the Bald Range wildfire forced about 20,000 people from their homes in Summerland, Peachland and surrounding areas, with many evacuees finding shelter in Penticton. Long after the smoke clears, the impact can stay with the firefighters, emergency responders and families who lived through it. PTSD is a recognized occupational risk for first responders, and this season was a reminder of why better treatment options matter.
“PTSD touches so many people in our community: first responders, people who’ve survived accidents or violence, families who lost homes to fire. Being part of rigorous, closely supervised research means people in the South Okanagan have a real voice in what the next generation of care looks like,” said Dr. Linda Grasswick, Principal Investigator for the study in Penticton.
PTSD can develop after experiencing or witnessing a traumatic event. It can involve intrusive memories, avoidance, changes in mood and heightened anxiety. Statistics Canada’s 2023 Survey on Mental Health and Stressful Events found that about 1 in 12 Canadian adults reported moderate to severe PTSD symptoms. Only a small number of medications are approved to treat PTSD, and many people do not find adequate relief from existing options.
“Trauma doesn’t end when the emergency does. People carry it home, to work and into their families, sometimes for years. Too many British Columbians living with PTSD have tried everything available and are still waiting for something that works for them. Bringing this research to four communities across the province means people don’t have to go to a big city or another country to be part of finding better options. They can do it close to home,” said Adam Watson, Clinical Operations Lead at Medical Arts Health Research Group.
About the Study
COMP 202 is a multicentre international study taking place at sites in multiple countries. The study is looking at whether the investigational medication can safely help reduce PTSD symptoms. No conclusions about its effectiveness have been reached. Participants receive care and support from a dedicated study team throughout, and study-related visits, assessments and the investigational medication are provided at no cost.
Adults living with PTSD in the South Okanagan who would like to learn more can contact the study team confidentially at (888) 490-4320 or visiting www.healthresearch.ca. Reaching out does not commit anyone to participate.
About Medical Arts Health Research Group
Medical Arts Health Research Group conducts clinical research in Kelowna, Kamloops, Penticton, North Vancouver, Nanaimo and Calgary, contributing to medical knowledge in mental health, substance use, Alzheimer’s disease, diabetes, cardiovascular disease, obesity and other conditions. The organization is committed to bringing high-quality, ethical clinical research opportunities to the communities it serves. Learn more at www.healthresearch.ca.